Mobilisation of healthy donors with lenograstim and transplantation of HLA-genoidentical blood progenitors in 54 patients with hematological malignancies:: a pilot study

被引:17
作者
Blaise, D
Jourdan, E
Michallet, M
Jouet, JP
Boiron, JM
Michel, G
Faucher, C
Fégueux, N
Schuller, MP
Badri, N
Chabannon, C
Maraninchi, D
机构
[1] Inst J Paoli I Calmettes, Transplant & Cellular Therapy Unit, F-13273 Marseille, France
[2] CHU Montpellier, Montpellier, France
[3] CHU, Lyon, France
[4] CHU Lille, F-59037 Lille, France
[5] CHU, Bordeaux, France
[6] CHU, Marseille, France
[7] Lab Rhone Poulenc Rorer, Montrouge, France
关键词
blood cell transplantation; allogeneic; G-CSF; lenograstim;
D O I
10.1038/sj.bmt.1701505
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Blood cell transplantation (BCT) is now common practice in the autologous setting. We performed a pilot study of allogeneic BCT, collected after the priming of an HLA-identical sibling with a glycosylated rhu-G-CSF (lenograstim) (10 mu g/kg). Fifty-four patients were included (38 +/- 11; M/F = 33/21; CML (n = 17), AML (n = 14), ALL (n = 15); MDS (rt = 8)), Transplant procedures were standard (TBI regimen = 47 (87 %); MTX-CsA: 11 =37; CsA-PDN: n=17), No serious adverse events were reported in donors. A median of 11 (3.5-29.1)x 10(6)/kg CD34(+) cells, 332 (33-820)x 10(6)/kg CD3(+) cells were collected. Four patients did not engraft (early death: n=2; graft failure: n=2), Fifty-one patients initially recovered 0.5 x 10(9)/l ANC and 25 x 10(9)/l platelets at 15 (10-30) and 13 (9-188) days. 29/51 and 29/38 experienced grade greater than or equal to 2 acute and chronic GVHD, With a median follow-up of 25 months (18-36), relapse rate is 16%, +/- 8, survival and DFS probabilities are similar (50% -/+ 13), A better outcome is documented for patients under 45 years and in the early phase of the disease (n = 28), with an identical survival and DFS of 71% +/- 13, In conclusion, lenograstim is a potent rhu-G-CSF for mobilisation of allogeneic hematopoietic progenitors. Two-year follow-up indicates good haematological recovery but some concerns about graft failure and chronic GVHD have arisen deserving prospective evaluation.
引用
收藏
页码:1153 / 1158
页数:6
相关论文
共 34 条
  • [1] Peripheral blood stem cell apheresis in normal donors: Feasibility and yield of second collections
    Anderlini, P
    Lauppe, J
    Przepiorka, D
    Seong, D
    Champlin, R
    Korbling, M
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1997, 96 (02) : 415 - 417
  • [2] Anderlini P, 1997, BLOOD, V90, P903
  • [3] TRANSPLANTATION OF ALLOGENEIC PERIPHERAL-BLOOD STEM-CELLS MOBILIZED BY RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR
    BENSINGER, WI
    WEAVER, CH
    APPELBAUM, FR
    ROWLEY, S
    DEMIRER, T
    SANDERS, J
    STORB, R
    BUCKNER, CD
    [J]. BLOOD, 1995, 85 (06) : 1655 - 1658
  • [4] Bensinger WI, 1996, BLOOD, V88, P4132
  • [5] Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: A retrospective comparison with marrow transplantation
    Bensinger, WI
    Clift, R
    Martin, P
    Appelbaum, FR
    Demirer, T
    Gooley, T
    Lilleby, K
    Rowley, S
    Sanders, J
    Storb, R
    Buckner, CD
    [J]. BLOOD, 1996, 88 (07) : 2794 - 2800
  • [6] BLAISE D, 1992, BLOOD, V79, P2578
  • [7] IMPAIRMENT OF LEUKEMIA-FREE SURVIVAL BY ADDITION OF INTERLEUKIN-2-RECEPTOR ANTIBODY TO STANDARD GRAFT-VERSUS-HOST PROPHYLAXIS
    BLAISE, D
    OLIVE, D
    MICHALLET, M
    MARIT, G
    LEBLOND, V
    MARANINCHI, D
    [J]. LANCET, 1995, 345 (8958): : 1144 - 1146
  • [8] Demonstration of donor origin of CD34+ HLA-DR- bone marrow cells after allogeneic peripheral blood transplantation with a long follow-up
    Briones, J
    Urbano-Ispizua, A
    Orfao, A
    Marín, P
    Sierra, J
    Rovira, M
    Carreras, E
    Rozman, C
    Montserrat, E
    [J]. BONE MARROW TRANSPLANTATION, 1998, 21 (02) : 189 - 194
  • [9] CAHN JY, 1991, BONE MARROW TRANSPL, V7, P1
  • [10] Early establishment of chimerism in the B and T lymphoid lineages after transplantation of allogeneic mobilized blood cells in leukemic patients
    Chabannon, C
    Lafage, M
    Mozziconacci, MJ
    Faucher, C
    Maraninchi, D
    Blaise, D
    [J]. TRANSPLANTATION, 1997, 63 (11) : 1646 - 1652